DanielOscarPerskyMD

PubMed

• A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma.
  Michael Durando, Ajay K Gopal, Joseph Tuscano, Daniel Persky
  The Oncologist. 2024-04-04
• Optimizing assessment of CD30 expression in Hodgkin lymphoma by controlling for low expression.
  Shoib Sarwar, Margaret E Tome, Dean Billheimer, Catherine Spier, Catharine L Smith
  Histology and Histopathology. 2024-03-01
• 2 citations
  Extranodal presentation in limited-stage diffuse large Bcell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001.
  Deborah M Stephens, Hongli Li, Louis S Constine, Thomas J Fitzgerald, John P Leonard
  Haematologica. 2022-11-01

Journal Articles

• Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma (L-NN-MCL) with P53 Gene Re-arrangement/Mutation Is Highly Responsive to Rituximab/Ibrutinib Combination Therapy  
  Shahram Mori, Juan Varela, Steven C Goldstein, Daniel O Persky, Clinical Lymphoma, Myeloma, & Leukemia
• Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/vincristine in Relapsed/refractory Aggressive B-cell Lymphoma  
  Daniel Persky, Soham Puvvada, Catherine Spier, Gregory Monohan, Ari VanderWalde, Daruka Mahadevan, Clinical Cancer Research

Abstracts/Posters

• Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
  Daniel O. Persky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
  Daniel O. Persky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)
  Daniel O. Persky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated ...
  Daniel O. Persky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018